1. Shenoi S, Heysell S, Moll A, Friedland G. Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community. Curr Opin Infect Dis 2009;22:11-17. PMID:
19532076.
2. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010;375:1830-1843. PMID:
20488523.
3. Marks SM, Flood J, Seaworth B, Hirsch-Moverman Y, Armstrong L, Mase S, et al. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007. Emerg Infect Dis 2014;20:812-821. PMID:
24751166.
4. Rajbhandary SS, Marks SM, Bock NN. Costs of patients hospitalized for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2004;8:1012-1016. PMID:
15305486.
5. Althomsons SP, Cegielski JP. Impact of second-line drug resistance on tuberculosis treatment outcomes in the United States: MDR-TB is bad enough. Int J Tuberc Lung Dis 2012;16:1331-1334. PMID:
22863311.
7. Heysell SK, Moore JL, Keller SJ, Houpt ER. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 2010;16:1546-1553. PMID:
20875279.
9. Chan ED, Laurel V, Strand MJ, Chan JF, Huynh ML, Goble M, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004;169:1103-1109. PMID:
14742301.
10. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002;62:2169-2183. PMID:
12381217.
11. California Department of Public Health. Curry International TB Center. Drug-resistant tuberculosis: a survival guide for clinicians. 2nd edition. Oakland: Curry International TB Center; 2008. p. 66-67.
12. Mpagama SG, Ndusilo N, Stroup S, Kumburu H, Peloquin CA, Gratz J, et al. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2014;58:782-788. PMID:
24247125.
13. Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014;74:839-854. PMID:
24846578.
14. Casali N, Nikolayevskyy V, Balabanova Y, Ignatyeva O, Kontsevaya I, Harris SR, et al. Microevolution of extensively drugresistant tuberculosis in Russia. Genome Res 2012;22:735-745. PMID:
22294518.
15. Zaunbrecher MA, Sikes RD Jr, Metchock B, Shinnick TM, Posey JE. Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in
Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 2009;106:20004-20009. PMID:
19906990.
17. Rowlinson MC. ighth National Conference on Laboratory Aspects of Tuberculosis. Association of Public Health Laboratories. MICs in TB susceptibility testing: challenges and solutions for implementation. San Diego, CA, USA: 2013. 8 19-21.
18. Banu S, Rahman SM, Khan MS, Ferdous SS, Ahmed S, Gratz J, et al. Discordance across several methods for drug susceptibility testing of drug-resistant
Mycobacterium tuberculosis isolates in a single laboratory. J Clin Microbiol 2014;52:156-163. PMID:
24172155.
19. Lee J, Armstrong DT, Ssengooba W, Park JA, Yu Y, Mumbowa F, et al. Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugs. Antimicrob Agents Chemother 2014;58:11-18. PMID:
24100497.
20. Chigutsa E, Meredith S, Wiesner L, Padayatchi N, Harding J, Moodley P, et al. Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2012;56:3857-3863. PMID:
22564839.
21. Hung WY, Yu MC, Chiang YC, Chang JH, Chiang CY, Chang CC, et al. Serum concentrations of cycloserine and outcome of multidrug-resistant tuberculosis in Northern Taiwan. Int J Tuberc Lung Dis 2014;18:601-606. PMID:
24903799.
22. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012;367:1508-1518. PMID:
23075177.
23. Peloquin CA, Berning SE, Huitt GA, Childs JM, Singleton MD, James GT. Once-daily and twice-daily dosing of p-aminosalicylic acid granules. Am J Respir Crit Care Med 1999;159:932-934. PMID:
10051275.
24. Heysell SK, Houpt ER. Optimizing second-line therapy for drug-resistant tuberculosis: the additive value of sequencing for multiple resistance loci. Antimicrob Agents Chemother 2011;55:3968-3969. PMID:
21757612.
25. Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, et al. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of
Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011;55:2032-2041. PMID:
21300839.